Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
744 Tablet
- Development stage
- Unknown
- Lead developer
- ViiV Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The "744 Tablet" is an oral formulation of cabotegravir (GSK1265744), an HIV integrase strand transfer inhibitor (INSTI). It is developed for the treatment and prevention of HIV-1 infection. Cabotegravir works by blocking the HIV enzyme integrase, preventing HIV from multiplying. The oral tablet form is used for daily administration, often as a lead-in to long-acting injectable formulations.
- Brand names
- Vocabria
- Other names
- Cabotegravir744 LAGSK-1265744GSK1265744GSK 1265744GSK744 LAGSK-744 LAGSK 744 LAGSK744 LAPGSK-744 LAPGSK 744 LAPS-265744S265744S 265744cabotegravir LAcabotegravir sodium
02
Targets
Integrase allosteric pocket (HIV)
Beyond the preview
Go deeper on 744 Tablet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 744 Tablet.